Verteporfin Photodynamic Therapy Combined With Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology

Volumn 116, Issue 4, 2009, Pages

  Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; TRIAMCINOLONE; VERTEPORFIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; IRITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; SCORING SYSTEM; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UVEITIS; VISION; VISUAL ACUITY;

EID: 63149165854     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.12.057     Document Type: Article

References (38)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119 (2001) 198-207
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131 (2001) 541-560
3. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123 (2005) 448-457
4. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP Report No. 3. Ophthalmology 110 (2003) 667-673
5. Rosenfeld P.J., Saperstein D.A., Bressler N.M., et al. Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology 111 (2004) 1725-1733
6. "Improvement After Verteporfin Therapy" Writing Committee for the TAP Study Group. Improvement after verteporfin therapy. [letter]. Arch Ophthalmol 121 (2003) 415-416
7. Rosenfeld P.J., Brown D.M., Heier J.S., et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
8. Brown D.M., Kaiser P.K., Michels M., et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
9. Genentech. Avastin (bevacizumab) full prescribing information (2006), Genentech, San Francisco, CA. http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp Accessed May 30, 2007
10. FDA grants accelerated approval of Avastin in combination with paclitaxel chemotherapy for first-line treatment of advanced HER2-negative breast cancer. [press release] (2008), Genentech, South San Francisco, CA. February 22 http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=11027 Accessed March 11, 2008
11. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
12. Bashshur Z.F., Bazarbachi A., Schakal A., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
13. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase I dose-escalation study. Invest Ophthalmol Vis Sci 47 (2006) 4569-4578
14. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
15. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
16. Kaiser P.K. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 23 (2007) 477-487
17. Schmidt-Erfurth U., and Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45 (2000) 195-214
18. Adamis A.P., and Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina 25 (2005) 111-118
19. Spaide R.F. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141 (2006) 149-156
20. Kaiser P.K. Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. Curr Med Res Opin 21 (2005) 705-713
21. Augustin A.J., and Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 141 (2006) 638-645
22. Spaide R.F., Sorenson J., and Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110 (2003) 1517-1525
23. Augustin A.J., and Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 14-22
24. Lazic R., and Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114 (2007) 1179-1185
25. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
26. Heier J.S., Boyer D.S., Ciulla T.A., et al. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 124 (2006) 1532-1542
27. Dhalla M.S., Shah G.K., Blinder K.J., et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 26 (2006) 988-993
28. Ladewig M.S., Karl S.E., Hamelmann V., et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246 (2008) 17-25
29. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 245 (2007) 1273-1280
30. Augustin A.J., Puls S., and Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27 (2007) 133-140
31. Michels S., Prager F., Bakri S.J., and Wachtlin J. Bevacizumab for ophthalmic diseases. Expert Rev Ophthalmol 2 (2007) 369-378
32. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group, and Verteporfin in Photodynamic Therapy (VIP) Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol 137 (2004) 683-696
33. Fung A.E., Lalwani G.A., Rosenfeld P.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143 (2007) 566-583
34. Regillo C.D., Brown D.M., Abraham P., et al. PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 145 (2008) 239-248
35. Falkenstein I.A., Cochran D.E., Azen S.P., et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and Early Treatment Diabetic Retinopathy Study charts. Ophthalmology 115 (2008) 319-323
36. ClinicalTrials.gov. NCT00436553. Efficacy/safety of verteporfin photodynamic therapy and ranibizumab compared with ranibizumab in patients with subfoveal choroidal neovascularization. http://www.clinicaltrials.gov/ct2/show/NCT00436553 Accessed June 13, 2008
37. ClinicalTrials.gov. NCT00492284. Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL). http://www.clinicaltrials.gov/ct2/show/NCT00492284 Accessed June 13, 2008
38. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group, and Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study report no. 4. Retina 24 (2004) 1-12